Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15540573 | 0.87 | SMN1; SMN2 (0.66) | ALDH1A1CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL31449970 | 0.85 | ALDH1A1 (0.44) | ALDH1A1CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL114121 | 0.84 | ALDH1A1 (0.57) | ALDH1A1CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL5982888 | 0.83 | NR4A1 (0.61) | ALDH1A1CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL23202512 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CYP3A4MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL3279318 | 0.82 | ALDH1A1 (0.61) | ALDH1A1CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL27817544 | 0.81 | TUBB4A (0.58) | KDM4ECYP1A2 | |
| SCHEMBL29568160 | 0.81 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL91981 | 0.81 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL234263 | 0.80 | ALDH1A1 (0.64) | ALDH1A1CYP3A4MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478474-B | Amide compound and preparation method thereof | 中国科学院宁波材料技术与工程研究所 | 2023-06-30 | — | — | CN | claimed |
| CN-102199099-B | Method for preparing 3-bromo-4-methoxyaniline | UNIV CHANGZHOU | 2013-12-18 | — | — | CN | claimed |
| CN-102199099-A | Method for preparing 3-bromo-4-methoxyaniline | UNIV CHANGZHOU | 2011-09-28 | — | — | CN | claimed |
| US-12516058-B2 | Small-molecule compounds for controlling endosomal toll-like receptors and therapeutic agent for autoimmune diseases using same | S＆K THERAPEUTICS (KR) | 2026-01-06 | — | — | US | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| WO-2025235719-A1 | DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-3796905-B1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | UNIV ILLINOIS (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250223264-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-07-10 | — | — | US | disclosed |
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12286407-B2 | Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-29 | — | — | US | disclosed |
| CN-119462529-A | Method for synthesizing quinazoline diketone compound | 广西师范大学 | 2025-02-18 | — | — | CN | disclosed |
| US-20010017155-A1 | Of monovinylated triarylamine monomers; use in light emitting diodes or as components of photorefractive materials | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2001-08-30 | — | — | US | disclosed |
| US-6100254-A | Inhibitors of protein tyrosine kinases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-08-08 | — | — | US | disclosed |
| US-6046195-A | Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2000-04-04 | — | — | US | disclosed |
| CN-1225009-A | Pentafluorobenzenesulfonamides and analogs thereof | TULARIK INC (US) | 1999-08-04 | — | — | CN | disclosed |
| EP-0929554-A1 | SPIRO-AZACYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1999-07-21 | — | — | EP | disclosed |
| CN-1223656-A | Spiro-piperidine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME (GB) | 1999-07-21 | — | — | CN | disclosed |
| WO-1999019306-A2 | 2,3-BENZODIAZEPIN-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF PROTEIN TYROSINE KINASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-04-22 | — | — | WO | disclosed |
| WO-1998013369-A1 | SPIRO-AZACYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| US-5455252-A | Antiinflammatory agent, immunosuppressant, antiallergen, skin disorders, bronchodilator, analgesic | SYNTEX (U.S.A.) INC. (US) | 1995-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | ALDH1A1 238/4885CYP3A4 3671/4885MEN1 1305/4885 |
| US-12286407-B2 | Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases | ESR2, ESRRG, GPER1 | ALDH1A1 1027/4885CYP3A4 1246/4885MEN1 4465/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | ALDH1A1 545/4885CYP3A4 9/4885MEN1 4869/4885 |
| US-20250223264-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | ESR2, ESRRG, GPER1 | ALDH1A1 1027/4885CYP3A4 1246/4885MEN1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.